Additionally, trastuzumab IgE, an antibody raised against HER2/neu (a receptor common to HER2+ breast cancer) provided equal if not added cytotoxic benefit compared to the IgG1 form of the same antibody [166]. Here, IGHE is linked to breast cancer.